Last $7.10 USD
Change Today +0.04 / 0.57%
Volume 49.0K
MEIP On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 2:55 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

mei pharma inc (MEIP) Snapshot

Open
$7.08
Previous Close
$7.06
Day High
$7.11
Day Low
$6.60
52 Week High
03/28/14 - $13.98
52 Week Low
06/25/14 - $5.51
Market Cap
153.4M
Average Volume 10 Days
112.4K
EPS TTM
$-1.74
Shares Outstanding
21.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEI PHARMA INC (MEIP)

Related News

No related news articles were found.

mei pharma inc (MEIP) Related Businessweek News

No Related Businessweek News Found

mei pharma inc (MEIP) Details

MEI Pharma, Inc., a development-stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. Its lead drug candidate is Pracinostat, an orally available histone deacetylase inhibitor, which is in Phase II clinical trial for the treatment of hematologic diseases, such as myelodysplastic syndrome and acute myeloid leukemia. The company’s clinical development pipeline also includes two isoflavone-based drug candidates comprising ME-143, a NADH oxidase inhibitor drug candidate that is in Phase II clinical trial for the treatment of ovarian cancer; ME-344, an anti-cancer agent, which is in Phase I clinical trial for the treatment of cancer; and PWT143, which is in pre-clinical development for the treatment of cancer. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited.

13 Employees
Last Reported Date: 09/19/13
Founded in 2000

mei pharma inc (MEIP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $675.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $343.8K
Chief Medical Officer
Total Annual Compensation: $241.2K
Compensation as of Fiscal Year 2013.

mei pharma inc (MEIP) Key Developments

MEI Pharma, Inc.(NasdaqCM:MEIP) dropped from Russell 2000 Index

MEI Pharma, Inc. will be removed from the Russell 2000 Index.

MEI Pharma, Inc.(NasdaqCM:MEIP) dropped from Russell 3000 Index

MEI Pharma, Inc. will be removed from the Russell 3000 Index.

MEI Pharma Inc. Initiates Clinical Study of Mitochondrial Inhibitor Drug Candidate ME-344 in Small Cell Lung and Ovarian Cancers

MEI Pharma Inc. announced that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin(R) (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers. The open-label study is expected to enroll up to 64 patients with preliminary data anticipated by the first quarter of 2015. In October 2013, results from a Phase I clinical study of ME-344 were announced showing preliminary evidence of single-agent activity in patients with refractory solid tumors, including eight of 21 evaluable patients (38%) who achieved stable disease or better. Notably, one patient with small cell lung cancer achieved a confirmed partial response and still remains on study after more than 89 weeks. ME-344 was generally well tolerated in the study at doses equal to or less than 10 mg/kg delivered on a weekly schedule for extended durations. Dose limiting toxicities were observed at both the 15 and 20 mg/kg dose levels, consisting primarily of Grade 3 peripheral neuropathy. The Phase Ib study now underway is evaluating the safety and tolerability of intravenous ME-344 in combination with Hycamtin, a chemotherapy approved by the U.S. Food & Drug Administration for the treatment of small cell lung, ovarian and cervical cancers. The initial stage of the study will establish the maximum tolerated dose (MTD) of ME-344 in combination with Hycamtin in up to 24 patients. Once the MTD has been determined, the study will enroll an additional 40 patients into two cohorts: relapsed/refractory small cell lung cancer and platinum-refractory ovarian cancer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MEIP:US $7.10 USD +0.04

MEIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MEIP.
View Industry Companies
 

Industry Analysis

MEIP

Industry Average

Valuation MEIP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEI PHARMA INC, please visit www.meipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.